Parameters of dynamic spirometry before and after administration of salbutamol in COPD patients

1 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2021 report [internet], Global Initiative for Chronic Obstructive Lung Disease; 2021 [cited 2021 Aug 8]. Available from: https://goldcopd.org/ Search in Google Scholar

2 Buist AS, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;1;370(9589):741–50. 10.1016/S0140-6736(07)61377-4 [PubMed] [CrossRef] [Google Scholar] Search in Google Scholar

3 Chronic obstructive pulmonary disease (COPD) in Vietnam [internet]. Geneva: World Health Organization; 2021. [cited 2021 Oct 20]. Available from: https://www.who.int/vietnam/health-topics/chronic-obstructive-pulmonary-disease-copd Search in Google Scholar

4 Chronic obstructive pulmonary disease (COPD). Geneva: World Health Organization; 2021. [cited 2021 Oct 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Search in Google Scholar

5 Beaglehole R, Bonita R, Horton R, et al. Priority actions for the noncommunicable disease crisis. Lancet. 2011;377:1438–1447 Search in Google Scholar

6 Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397:928–940. Search in Google Scholar

7 Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021;398:1569–1580. Search in Google Scholar

8 Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019;23:1131–1141. Search in Google Scholar

9 WHO . World Health Organization; Geneva: 2013. [cited 2023 Oct 24] Global Action Plan for the prevention and control of noncommunicable diseases 2013–2020. Search in Google Scholar

10 Global Initiative for Chronic Obstructive Lung Disease. 2023. [cited 2023 Oct 24] Available from: https://goldcopd.org/2023-gold-report-2/ Search in Google Scholar

11 Alsuwaigh R, Yii A, Loh CH, Xu X, Bahety P, Navarro Rojas AA, Milea D, Tee A. A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore. J Thorac Dis. 2024;16(2):847-861. doi: 10.21037/jtd-22-1769. Epub 2024 Feb 21. PMID: 38505044; PMCID: PMC10944796. Search in Google Scholar

12 Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206:1317–1325. Search in Google Scholar

13 Global Initiative for Chronic Obstructive Lung Disease. 2022. [cited 2023 Oct 24]Available from: www.goldcopd.org Search in Google Scholar

14 Agustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med. 2022;10:512–524. Search in Google Scholar

15 Vollmer WM, Gíslason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009; 343:588-597. Search in Google Scholar

16 Agusti A, Vogelmeier CF. GOLD 2024: a brief overview of key changes. J Bras Pneumol. 2023;49(6):e20230369. doi: 10.36416/1806-3756/ e20230369. PMID: 38126685; PMCID: PMC10760434 Search in Google Scholar

17 Cazzola M. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal. 2008;31.2: 416-469. Search in Google Scholar

18 Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;1154:957-965. Search in Google Scholar

19 Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med. 2007;101(6):1355-62. Search in Google Scholar

20 Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. The Lancet Respiratory Medicine 2013;1(7): 564-573. Search in Google Scholar

21 Svensson L,  Ankerst J,  Bjermer L,  Tufvesson E. Airway resistance and reactance in COPD patients and healthy smokers and effect of bronchodilators. European Respiratory Journal. 2011;38(55) : 4053. Search in Google Scholar

22 Kanda S, Fujimoto K, Komatsu Y, Yasuo M, Hanaoka M, Kubo K. Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. Intern Med. 2010;49(1):23-30. Search in Google Scholar